Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse

This clinical study is the initiative of the FOSTER (Fight OsteoSarcoma Through European Research) consortium and Gustave Roussy, which is the sponsor. Its aim is to evaluate the biology of tumour in greater depth by collecting samples of the tumour during the biopsy at diagnosis, and blood samples. This study is a platform study that evolves over time. This means that it allows for the evaluation of several treatments or therapeutic strategies within a single clinical trial, which can be modified and adapted over time. The FOSTER evolving study platform aim to implement a comprehensive strat

Trial Details

NCT ID
NCT07871864
Phase
PHASE3
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Status
RECRUITING
Cancer Type
Osteosarcoma Sarcoma
Interventions
  • Experimental group : Cabometyx ® 40mg/m2/day (Max: 60mg/day) , Treatment schedule : Daily**, day 1-28 during 4 weeks (ie. 1 cycle) during 12 cycles
Locations (sample)
  • Aarhus, Denmark|56.15674,10.21076
  • Copenhagen, Denmark|55.67594,12.56553
  • Herlev, Denmark|55.72366,12.43998
  • Helsinki, Finland|60.16952,24.93545
  • Kuopio, Finland|62.89238,27.67703

Key Eligibility Criteria

  • Newly diagnosed, biopsy-proven, high-grade osteosarcoma,
  • Patient considered medically fit to receive systemic treatment,
  • Planned systemic therapy according to national guidelines and age
  • Written informed consent from patients or for minor, from their parents/ legal representatives, before enrolment and any study-related procedure.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →